Literature DB >> 8698626

Induction of MAGE genes in lymphoid cells by the demethylating agent 5-aza-2'-deoxycytidine.

S Shichijo1, A Yamada, K Sagawa, O Iwamoto, M Sakata, K Nagai, K Itoh.   

Abstract

MAGE genes encoding tumor antigens recognized by cytotoxic T lymphocytes are appropriate target molecules for specific immunotherapy of cancer. We have investigated whether the demethylating agent 5-aza-2'-deoxycytidine (DAC) induces MAGE-1, -2, -3, and -6 in normal and malignant lymphoid cells. DAC induced these MAGE genes in both PHA/interleukin-2 (IL-2)-activated T cells from healthy donors and MAGE-negative T and B cell leukemias in most cases. It also induced MAGE-1 in IL-2-dependent T cell clones and all MAGE genes tested in Epstein-Barr virus-transformed B cell lines. Expression of MAGE-1 protein in the cells was confirmed by western blot analysis with anti-MAGE-1 polyclonal antibody. Therefore, demethylation is a potent stimulus to induce MAGE genes in both normal and malignant lymphoid cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8698626      PMCID: PMC5921158          DOI: 10.1111/j.1349-7006.1996.tb00288.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  16 in total

Review 1.  DNA methylation and gene expression.

Authors:  A Razin; H Cedar
Journal:  Microbiol Rev       Date:  1991-09

2.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

3.  Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.

Authors:  J Weber; M Salgaller; D Samid; B Johnson; M Herlyn; N Lassam; J Treisman; S A Rosenberg
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

4.  Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene.

Authors:  C De Smet; S J Courtois; I Faraoni; C Lurquin; J P Szikora; O De Backer; T Boon
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

5.  Detection of MAGE-4 protein in lung cancers.

Authors:  S Shichijo; A Hayashi; S Takamori; R Tsunosue; T Hoshino; M Sakata; T Kuramoto; K Oizumi; K Itoh
Journal:  Int J Cancer       Date:  1995-06-22       Impact factor: 7.396

6.  Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis.

Authors:  K Takahashi; S Shichijo; M Noguchi; M Hirohata; K Itoh
Journal:  Cancer Res       Date:  1995-08-15       Impact factor: 12.701

7.  Immunopathological mechanisms of human T cell lymphotropic virus type 1 (HTLV-I) uveitis. Detection of HTLV-I-infected T cells in the eye and their constitutive cytokine production.

Authors:  K Sagawa; M Mochizuki; K Masuoka; K Katagiri; T Katayama; T Maeda; A Tanimoto; S Sugita; T Watanabe; K Itoh
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

8.  Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601.

Authors:  P van der Bruggen; J P Szikora; P Boël; C Wildmann; M Somville; M Sensi; T Boon
Journal:  Eur J Immunol       Date:  1994-09       Impact factor: 5.532

9.  Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes.

Authors:  B Gaugler; B Van den Eynde; P van der Bruggen; P Romero; J J Gaforio; E De Plaen; B Lethé; F Brasseur; T Boon
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

10.  A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.

Authors:  C Traversari; P van der Bruggen; I F Luescher; C Lurquin; P Chomez; A Van Pel; E De Plaen; A Amar-Costesec; T Boon
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

View more
  9 in total

1.  Androgen receptor molecular biology and potential targets in prostate cancer.

Authors:  Elizabeth M Wilson
Journal:  Ther Adv Urol       Date:  2010-06

Review 2.  Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.

Authors:  Adam Jona; Anas Younes
Journal:  Blood Rev       Date:  2010-09-15       Impact factor: 8.250

3.  Epigenetic drug combination induces genome-wide demethylation and altered gene expression in neuro-ectodermal tumor-derived cell lines.

Authors:  Floor A M Duijkers; Renee X de Menezes; Inès J Goossens-Beumer; Dominique J P M Stumpel; Pieter Admiraal; Rob Pieters; Jules P P Meijerink; Max M van Noesel
Journal:  Cell Oncol (Dordr)       Date:  2013-07-18       Impact factor: 6.730

4.  Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.

Authors:  Jasmine Zain; Owen A O'Connor
Journal:  Invest New Drugs       Date:  2010-12-04       Impact factor: 3.850

Review 5.  Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.

Authors:  Michael Dickinson; Ricky W Johnstone; H Miles Prince
Journal:  Invest New Drugs       Date:  2010-12-14       Impact factor: 3.850

Review 6.  Histone deacetylase inhibitors in Hodgkin lymphoma.

Authors:  Daniela Buglio; Anas Younes
Journal:  Invest New Drugs       Date:  2010-12-03       Impact factor: 3.850

7.  Cancer/testis antigens and gametogenesis: a review and "brain-storming" session.

Authors:  Martins Kalejs; Jekaterina Erenpreisa
Journal:  Cancer Cell Int       Date:  2005-02-16       Impact factor: 5.722

8.  Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells.

Authors:  Alexei F Kirkin; Karine N Dzhandzhugazyan; Per Guldberg; Johnny Jon Fang; Rikke S Andersen; Christina Dahl; Jann Mortensen; Tim Lundby; Aase Wagner; Ian Law; Helle Broholm; Line Madsen; Christer Lundell-Ek; Morten F Gjerstorff; Henrik J Ditzel; Martin R Jensen; Walter Fischer
Journal:  Nat Commun       Date:  2018-03-06       Impact factor: 14.919

9.  MAGE, BAGE and GAGE: tumour antigen expression in benign and malignant ovarian tissue.

Authors:  A M Gillespie; S Rodgers; A P Wilson; J Tidy; R C Rees; R E Coleman; A K Murray
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.